CytomX Therapeutics
CTMX
CTMX
81 hedge funds and large institutions have $57.2M invested in CytomX Therapeutics in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 21 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
2% less funds holding
Funds holding: 83 → 81 (-2)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
Holders
81
Holding in Top 10
–
Calls
$56K
Puts
$54K
Top Buyers
| 1 | +$1.9M | |
| 2 | +$654K | |
| 3 | +$612K | |
| 4 |
D.E. Shaw & Co
New York
|
+$206K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$120K |
Top Sellers
| 1 | -$950K | |
| 2 | -$799K | |
| 3 | -$744K | |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$692K |
| 5 |
E
Ergoteles
New York
|
-$405K |